{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:06:23Z","timestamp":1762909583596,"version":"3.45.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.resmer.2023.101056","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:33:03Z","timestamp":1696948383000},"page":"101056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-7880","authenticated-orcid":false,"given":"Isabelle","family":"Mah\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvy","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Couturaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.resmer.2023.101056_bib0001","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.resmer.2023.101056_bib0002","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.resmer.2023.101056_bib0003","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial","volume":"314","author":"Lee","year":"2015","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.resmer.2023.101056_bib0004","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.resmer.2023.101056_bib0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"issue":"15","key":"10.1016\/j.resmer.2023.101056_bib0006","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.resmer.2023.101056_bib0007","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.resmer.2023.101056_bib0008","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"Posch","year":"2015","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.resmer.2023.101056_bib0009","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.resmer.2023.101056_bib0010","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.resmer.2023.101056_bib0011","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.resmer.2023.101056_bib0012","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101056_bib0013","article-title":"Rivaroxaban versus Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial","author":"Planquette","year":"2021","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.resmer.2023.101056_bib0014","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.resmer.2023.101056_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"Cohen","year":"2017","journal-title":"Thrombosis and haemostasis"},{"issue":"32","key":"10.1016\/j.resmer.2023.101056_bib0016","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2013.51.7433","article-title":"Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study","volume":"32","author":"Napolitano","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.resmer.2023.101056_bib0017","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"10.1016\/j.resmer.2023.101056_bib0018","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.resmer.2023.101056_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082256","article-title":"Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study","volume":"12","author":"Mahe","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.resmer.2023.101056_bib0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2020.02.005","article-title":"Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism","volume":"188","author":"Schmidt","year":"2020","journal-title":"Thrombosis research"},{"issue":"11","key":"10.1016\/j.resmer.2023.101056_bib0021","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14561","article-title":"Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study","volume":"17","author":"Di Nisio","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.resmer.2023.101056_bib0022","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jth.14752","article-title":"Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)","volume":"18","author":"Marshall","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.resmer.2023.101056_bib0023","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site","volume":"130","author":"Mahe","year":"2017","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.resmer.2023.101056_bib0024","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.chest.2015.10.069","article-title":"Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer","volume":"149","author":"van der Hulle","year":"2016","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.resmer.2023.101056_bib0025","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/a-1647-9896","article-title":"Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study","volume":"122","author":"Mahe","year":"2022","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.resmer.2023.101056_bib0026","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis","volume":"13","author":"Schulman","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.resmer.2023.101056_bib0027","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"issue":"1","key":"10.1016\/j.resmer.2023.101056_bib0028","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb Res"},{"issue":"23","key":"10.1016\/j.resmer.2023.101056_bib0029","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.jcin.2016.08.039","article-title":"Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy","volume":"9","author":"Mellado","year":"2016","journal-title":"JACC Cardiovascular interventions"},{"issue":"2","key":"10.1016\/j.resmer.2023.101056_bib0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.resmer.2023.101056_bib0031","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jth.12071","article-title":"International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer","volume":"11","author":"Debourdeau","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.resmer.2023.101056_bib0032","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.thromres.2014.11.020","article-title":"Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients","volume":"135","author":"Delluc","year":"2015","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.resmer.2023.101056_bib0033","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1538-7836.2007.02613.x","article-title":"A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)","volume":"5","author":"Kovacs","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101056_bib0034","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2017.04.003","article-title":"A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)","volume":"162","author":"Davies","year":"2018","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.resmer.2023.101056_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jth.13172","article-title":"Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients","volume":"14","author":"van der Hulle","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.resmer.2023.101056_bib0036","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1111\/j.1538-7836.2012.04868.x","article-title":"Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study","volume":"10","author":"Sahut D'Izarn","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"20","key":"10.1016\/j.resmer.2023.101056_bib0037","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.18.01977","article-title":"Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study","volume":"37","author":"Kraaijpoel","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.resmer.2023.101056_bib0038","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"14","key":"10.1016\/j.resmer.2023.101056_bib0039","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2013-04-460162","article-title":"Treatment of cancer-associated thrombosis","volume":"122","author":"Lee","year":"2013","journal-title":"Blood"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041223000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041223000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:03:15Z","timestamp":1762909395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041223000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":39,"alternative-id":["S2590041223000685"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2023.101056","relation":{},"ISSN":["2590-0412"],"issn-type":[{"type":"print","value":"2590-0412"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2023.101056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101056"}}